Summary: Given that everyone is getting older and more prone to disease, medical innovation is one of the most important measures, if not the most important measure, of a successful health policy. Technological acceleration, including advances in genomics and stem cell research, suggest that we are on the cusp of a golden age of medical innovation. But government-imposed price controls and other policies can reduce the incentives for devising new treatments, resulting in preventable death and illness. This panel will look at the effect of Obamacare, and the policies of the FDA on innovation. More generally, will the current regulatory processes and reimbursement policies equipped to manage the next generation of personalized medicine and diagnostic devices? This program was presented on February 21, 2015, as part of the 2015 Federalist Society National Student Symposium. -- Featuring: Mr. Peter Huber, Senior Fellow, Manhattan Institute; Ms. Lindsay Kelly, Special Counsel, Irell & Manella LLP; and Mr. Gerald Masoudi, Partner, Covington & Burling LLP; former Chief Counsel, Food and Drug Administration. Moderator: Hon. Thomas B. Griffith, U.S. Court of Appeals, District of Columbia Circuit.
